The Claim
The specificity of 18F-PSMA-1007 PET/CT for detecting pelvic lymph node metastases in high-risk prostate cancer is high (96–98%), and this level of specificity is comparable to that of whole-body MRI and CT, indicating that false-positive results are rare and the modality does not overcall benign lymph nodes as malignant.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A special kind of scan called 18F-PSMA-1007 PET/CT is really good at telling apart cancerous lymph nodes in the pelvis from harmless ones in men with high-risk prostate cancer — it hardly ever makes a mistake and is just as accurate as MRI or CT scans.
See the scientific wording
The specificity of 18F-PSMA-1007 PET/CT for detecting pelvic lymph node metastases in high-risk prostate cancer is high (96–98%), comparable to whole-body MRI and CT, indicating that false-positive results are rare and the modality does not overcall benign nodes as cancer.
What the research says
1 studyThis study found that the 18F-PSMA-1007 PET/CT scan correctly identified healthy lymph nodes as not cancerous 98% of the time — just like the claim said — and did better than MRI and CT at finding real cancer nodes without making too many mistakes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.